Iron monosilicide

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

Retrieved on: 
Wednesday, January 3, 2024
Health, Hospitals, Genetics, General Health, Pharmaceutical, Biotechnology, RNA, Senior, Science, Drug discovery, Regulus Therapeutics, TANGO, Iron monosilicide, Research, Acquisition, Therapy, Novartis, Medicinal chemistry, CNS, Bangladesh Technical Education Board, Conditional, Central nervous system, Pharma, Lafayette College, Harvard University, Vaccine

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
  • He succeeds Si-ping Han, Ph.D., co-founder of Switch Therapeutics, who will transition to an advisory role and serve on Switch’s Scientific Advisory Board.
  • “Charles joins our leadership team with extensive expertise in oligonucleotide chemistry and RNA-based therapeutics, and we are delighted to welcome him to Switch.
  • He will play a crucial role as we continue driving our novel CASi platform forward for the treatment of central nervous system (CNS) diseases,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.

Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors

Retrieved on: 
Monday, July 10, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, IPO, Broad Institute, Central nervous system, University, Midas List, General partnership, Iron monosilicide, RNA, Conditional, Patient, Genome Research, Novo Nordisk, RNA interference, Therapy, Broad, Disease, Pharmaceutical industry, Vaccine

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Douglas Fambrough, Ph.D., as an independent director to its Board.
  • With an incredible track record of building successful RNA companies, Doug will bring strategic perspective as we advance CASi and continue to build our pipeline,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “I am honored to join the Switch Therapeutics Board of Directors and believe deeply in the promise of gene knockdown to address an array of unmet needs,” said Dr. Fambrough.
  • I look forward to partnering with the Switch team to advance the company’s pipeline and, ultimately, deliver important new medicines that dramatically improve patients’ lives.”

Switch Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Carbon, Tissue, Amgen, University of Bristol, University of East London, Migraine, University, Senior, Doctor of Philosophy, Schizophrenia, CSO, P. R. Mallory and Co Inc, Western University, Rochester, Thomas Jefferson University, Pulsus Group, Nitric oxide, Coronavirus Scientific Advisory Board, DRS, Janssen, Physiology, Research, Iron monosilicide, Johns Hopkins School of Medicine, RNA, Genentech, Princeton University, Drexel University, CNS, Conditional, Pain, Discovery, Lilly, Molecular neuroscience, Outline of health sciences, Novo Nordisk, RNA interference, Merck, Therapy, Oligonucleotide, Western University of Health Sciences, Disease, Research fellow, Pharmaceutical industry, Erenumab, Neuroscience, Chemistry, Biology

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.
  • Marc Abrams, David Bredt and James Treanor to our company’s Scientific Advisory Board,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, they bring decades of experience in CNS and RNA therapies and we’re thrilled for them to join the Switch Therapeutics team.
  • Dr. Abrams spent the first 17 years of his career at Merck and Co., Inc in scientific positions of increasing responsibility.

Switch Therapeutics Expands Leadership Team with Key Appointments

Retrieved on: 
Tuesday, March 28, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Amgen, Central nervous system, University, Senior, Doctor of Philosophy, Vassar College, Business operations, University of California, Davis, Iron monosilicide, Medicine, Lawrence Livermore National Laboratory, RNA, Genentech, Onyx Pharmaceuticals, California Polytechnic State University, San Luis Obispo, RNA interference, Business administration, Upfront Ventures, Pleasure, Drug discovery, ASO, Physics, Growth, Kezar Stadium, Johnson & Johnson, Therapy, Disease, Pharmaceutical industry, Fine chemical, Biophysics, Biology

“I am delighted to welcome Craig and Michael to our leadership team,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.

Key Points: 
  • “I am delighted to welcome Craig and Michael to our leadership team,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, Craig and Michael bring substantial domain expertise, including their respective experience driving oligonucleotide research and providing operational leadership for growth and scale, which are highly relevant for Switch.
  • “I am thrilled to join the Switch Therapeutics team,” said Mr. Wolfe.
  • Following Switch’s $52 million financing announced earlier this month, Switch is operating from a position of strength, with a tremendous opportunity for further growth.

Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Professional Services, Health, Philanthropy, General Health, Pharmaceutical, Other Science, Research, Fund Raising, Science, Finance, RNA, Insight Partners, Eli Lilly and Company, Partner, RNA interference, Cell, Medicine, Small RNA, Therapy, Upfront Ventures, Venture, Iron monosilicide, Pharmaceutical industry, Vaccine

Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced its launch following $52 million of financing.

Key Points: 
  • Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced its launch following $52 million of financing.
  • Additionally, we can design CASi molecules to activate only in select cells, allowing for expansion into targets that may require precision RNAi approaches.
  • Switch was founded on the premise of a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science.
  • The sensor allows efficient delivery of the siRNA while regulating the siRNA’s activity to “switch on” only in selected cells.